Al-Razi Medical Company (TADAWUL:9572)
Saudi Arabia · Delayed Price · Currency is SAR 25.40
-0.60 (-2.31%)
Sep 6, 2026, 2:44 PM AST
Al-Razi Medical Company Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 39 | 46 | 90 | 91 | - | - | |
Market Cap Growth | -29.44% | -48.30% | -1.34% | - | - | - |
Enterprise Value | 49 | 59 | 98 | 97 | - | - |
Last Close Price | 25.40 | 30.50 | 59.00 | 59.80 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.40 | 56.57 | 509.93 | 132.51 | - | - |
PS Ratio | 0.51 | 0.62 | 1.46 | 1.48 | - | - |
PB Ratio | 1.61 | 1.97 | 3.96 | 4.06 | - | - |
P/TBV Ratio | 1.62 | 1.99 | 4.03 | 4.15 | - | - |
P/FCF Ratio | 9.04 | 12.05 | 81.55 | 91.19 | - | - |
P/OCF Ratio | 6.28 | 7.96 | 18.09 | 15.73 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.64 | 0.80 | 1.60 | 1.59 | - | - |
EV/EBITDA Ratio | 9.25 | 18.11 | 48.53 | 32.66 | - | - |
EV/EBIT Ratio | 29.53 | 39.01 | 256.62 | 62.66 | - | - |
EV/FCF Ratio | 11.51 | 15.37 | 89.31 | 97.71 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.45 | 0.51 | 0.38 | 0.48 | 0.32 | 0.27 |
Debt / EBITDA Ratio | 2.04 | 2.33 | 2.05 | 2.04 | 1.45 | 1.49 |
Debt / FCF Ratio | 2.54 | 3.10 | 7.86 | 10.73 | - | - |
Net Debt / Equity Ratio | 0.44 | 0.49 | 0.35 | 0.44 | 0.26 | -0.05 |
Net Debt / EBITDA Ratio | 3.09 | 3.56 | 3.89 | 3.30 | 1.68 | -0.36 |
Net Debt / FCF Ratio | 2.47 | 3.02 | 7.16 | 9.87 | -9.51 | 0.43 |
Asset Turnover | 1.54 | 1.58 | 1.42 | 1.39 | 1.26 | - |
Inventory Turnover | 2.72 | 2.63 | 2.23 | 1.98 | 1.84 | - |
Quick Ratio | 0.20 | 0.24 | 0.26 | 0.14 | 0.19 | 0.89 |
Current Ratio | 1.59 | 1.47 | 1.92 | 1.79 | 2.07 | 2.61 |
Return on Equity (ROE) | 4.81% | 3.55% | 0.78% | 2.99% | 8.43% | - |
Return on Assets (ROA) | 2.10% | 2.01% | 0.55% | 2.20% | 3.88% | - |
Return on Invested Capital (ROIC) | 4.06% | 3.55% | 0.40% | 3.17% | 8.12% | 8.99% |
Return on Capital Employed (ROCE) | 5.00% | 4.50% | 1.30% | 5.00% | 8.60% | 8.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.91% | 1.77% | 0.20% | 0.76% | - | - |
FCF Yield | 11.06% | 8.30% | 1.23% | 1.10% | - | - |
Dividend Yield | 6.10% | - | - | 2.65% | - | - |
Payout Ratio | - | - | - | 351.72% | 93.81% | - |
Total Shareholder Return | 6.10% | - | - | 2.65% | - | - |